CytRx touts survival data after aldoxorubicin hold lifted
This article was originally published in Scrip
CytRx has shared updates for more than a year from the Phase IIb soft tissue sarcoma (STS) clinical trial for aldoxorubicin, a modified version of the chemotherapy agent doxorubicin, but the company's stock traded flat on 22 January after CytRx reported a 1.6-month overall survival benefit in the trial.
You may also be interested in...
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.